🇺🇸 Risperidone Long Acting in United States

14 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 14

Most-reported reactions

1. Hospitalisation — 3 reports (21.43%)
2. Diarrhoea — 2 reports (14.29%)
3. Pyrexia — 2 reports (14.29%)
4. Aphasia — 1 report (7.14%)
5. Breast Tenderness — 1 report (7.14%)
6. Cardiomegaly — 1 report (7.14%)
7. Constipation — 1 report (7.14%)
8. Decreased Appetite — 1 report (7.14%)
9. Dizziness — 1 report (7.14%)
10. Drug Hypersensitivity — 1 report (7.14%)

Source database →

Frequently asked questions

Is Risperidone Long Acting approved in United States?

Risperidone Long Acting does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Risperidone Long Acting in United States?

Dartmouth-Hitchcock Medical Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.